Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study?
Kelman
Shalom E
SE
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004195:Disease Models, Animal; D006801:Humans; D007267:Injections; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects; D009900:Optic Nerve / Q000187:drug effects* / Q000503:physiopathology; D009902:Optic Neuritis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D010211:Papilledema / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D010865:Pilot Projects; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage*; D014822:Vitreous Body / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014221:Triamcinolone; D000068258:Bevacizumab